Xenon Pharmaceuticals Inc.
196 articles about Xenon Pharmaceuticals Inc.
-
Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss 2019 Financial Results and Provide Corporate Update
3/2/2020
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2019 financial and operating results after the close of U.S. financial markets on Monday, March 9, 2020.
-
Xenon Pharmaceuticals Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional Shares
2/14/2020
BURNABY, British Columbia, Feb. 14, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that the underwriters of its previously announced public offering of 3,750,000 common shares, which initially closed on January 27, 2020, have exercised in full their option to purchase an additional 562,500 common shares at the public offering price of $16.00 per share, raising additional gross proceeds of $9.0 million and increasin
-
Xenon Pharmaceuticals Announces Closing of its $60.0 Million Public Offering of Common Shares
1/27/2020
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the closing of its previously announced public offering of 3,750,000 common shares pursuant to its existing shelf registration statement at a public offering price of $16.00 per share
-
Xenon Pharmaceuticals Announces Pricing of $60.0 Million Public Offering of Common Shares
1/23/2020
Xenon Pharmaceuticals Inc., a clinical stage biopharmaceutical company, announced the pricing of its underwritten public offering of 3,750,000 common shares pursuant to its existing shelf registration statement at a public offering price of $16.00 per share.
-
Xenon Pharmaceuticals Announces Proposed Public Offering of Common Shares
1/22/2020
Xenon Pharmaceuticals Inc. announced that it has commenced an underwritten public offering of its common shares pursuant to its existing shelf registration statement.
-
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2020 and Provides Corporate Update
1/13/2020
Xenon’s Proprietary Programs Continue to Advance with Multiple Mid to Late Stage Clinical Trials Anticipated to be Underway in 2020
-
Xenon Pharmaceuticals Provides Updates on Partnered Neurology Pipeline Programs at the 2019 American Epilepsy Society (AES) Annual Meeting
12/7/2019
Overview of Clinical Stage XEN901 and Related Patient Survey to be Presented in the “Genetic Epilepsies – Updates in the Science and Diagnosis” Exhibit in Room 318-319 on Sunday, December 8th
-
Xenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at the 2019 American Epilepsy Society (AES) Annual Meeting
12/6/2019
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, announced today that it will provide updates on its proprietary, neurology programs at the American Epilepsy Society (AES) Annual Meeting held in Baltimore, MD.
-
Xenon Pharmaceuticals to Present at the 31st Annual Piper Jaffray Healthcare Conference
12/3/2019
Xenon Pharmaceuticals Inc. announced that Dr. Simon Pimstone, Xenon's Chief Executive Officer, will present at the 31st Annual Piper Jaffray Healthcare Conference in New York, NY on Wednesday, December 4, 2019 at 3:00 pm Eastern Time.
-
Xenon Pharmaceuticals to Host Conference Call and Webcast to Provide Corporate Update on License and Collaboration Agreement with Neurocrine Biosciences
12/2/2019
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, announced that it will host a conference call and live audio webcast at 8:30 am Eastern Time (5:30 am Pacific Time) today to provide a corporate update on the license and collaboration agreement that was announced this morning to develop first-in-class treatments for epilepsy with Neurocrine Biosciences, Inc.
-
Neurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for Epilepsy
12/2/2019
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Xenon Pharmaceuticals Inc. (Nasdaq: XENE) announced a license and collaboration agreement to develop first-in-class treatments for epilepsy.
-
Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences
11/15/2019
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's Chief Executive Officer, will participate in the following investor conferences and present a company update when noted:
-
Xenon Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update
11/5/2019
Xenon Pharmaceuticals Inc., a clinical stage biopharmaceutical company, reported its financial results for the third quarter ended September 30, 2019 and provided a corporate update.
-
Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2019 Financial Results and Provide Corporate Update
10/29/2019
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, announced that it will report its third quarter 2019 financial and operating results after the close of U.S. financial markets on Tuesday, November 5, 2019.
-
BioSpace Global Roundup, Sept. 12
9/12/2019
Companies and organizations from across Europe, Asia and North America share updates on their business and pipelines. -
Flexion Therapeutics and Xenon Pharmaceuticals Announce Flexion’s Acquisition of an Investigational NaV1.7 Inhibitor for the Treatment of Post-Operative Pain
9/9/2019
Flexion Therapeutics, Inc. and Xenon Pharmaceuticals Inc. announced that the companies have entered into a definitive agreement that provides Flexion with the global rights to develop and commercialize XEN402, a NaV1.7 inhibitor, for the management of post-operative pain.
-
Behind the Seizure™ Program Expansion Helps Speed the Diagnosis of Genetic Epilepsy in Younger Children Experiencing Unprovoked Seizures
2/26/2019
--Stoke Therapeutics and Xenon Pharmaceuticals Join Founders BioMarin and Invitae to Offer a No-Cost Epilepsy Gene Panel Testing Program for Children Up to 60 Months Who Have Had an Unprovoked Seizure-- [26-February-2019] SAN FRANCISCO , Feb. 26, 2019 /PRNewswire/ -- As Rare Disease Day focuses attention on the challenges of diagnosing rare, often genetic conditions,
-
Overall, the Swiss-based Roche announced a group sales increase of 7 percent, with the Pharmaceuticals Division up 7 percent, largely driven by sales of Ocrevus, Perjeta, Alecensa and Tecentriq.
-
Xenon Pharmaceuticals Outlines Key Milestones for 2018
1/8/2018
A look at Xenon's key goals for 2018.
-
Positive Preclinical Data from Xenon’s XEN901 Epilepsy Program to be Presented at the 71st American Epilepsy Society Annual Meeting
12/5/2017
XEN901 is a potent, selective Nav1.6 sodium channel inhibitor being developed by Xenon for the treatment of epilepsy.